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of biological sample exploitation. During PK calculations, many 
researchers merely use for dose the nominal amount declared, over-
looking the noticeable biases that may result in the assessment of PK 
parameters. The aim of this work was to evaluate the biases related 
to doses injected of a biosimilar drug in 2 Phase I clinical trials.
Patients (or Materials) and Methods: In trial A, 12 healthy volun-
teers received different doses of a biosimilar of interferon beta-1a by 
either subcutaneous (SC) or intravenous (IV) injection. The doses 
were prepared by partially emptying 0.5-mL syringes supplied by 
the manufacturer (drop count procedure). In trial B, 12 healthy vol-
unteers received 3 different formulations of the drug by IV injection 
(biosimilar without albumin [HSA], biosimilar with HSA and original 
brand [Rebif®]) and 2 different formulations as multiple SC injec-
tions (biosimilar HSA-free and original brand). In both trials, the 
actual dose administered was calculated as: D = C·V – losses. The 
product titer C was assessed by ELISA. The volume administered IV 
was assessed by weighting. Losses were evaluated by in vitro experi-
ments. Finally, the binding of 125I-interferon to HSA was evaluated 
by counting the free and HSA complexed molecule fractions sepa-
rated by gel filtration.
Results: Interferon was not significantly adsorbed onto the lines used 
for its IV administration. In trial A, the titer was very close to the one 
declared (96 ± 7%). In trial B, it differed significantly (156 ± 10% 
for biosimilar with/without HSA and 123 ± 5% for original for-
mulation). In trial A, the dose actually administered showed a large 
variability. The real injected volume could be biased up to 75% com-
pared with the theoretical volume (for the lower dose administered 
[ie, 0.03 mL]). This was mainly attributed to a partial re-aspiration 
of the drug solution before withdrawing the syringe needle. A strict 
procedure was therefore applied in trial B to avoid these inaccuracies. 
Finally, in trial B, 125I-Interferon beta-1a binding to HSA appeared 
time dependent and slow, reaching 50% after 16-hour incubation, 
which is close to steady state reported for the comparator Rebif®.
Conclusion: These practical examples (especially biases on actual 
titer and volume injected) illustrate that actual dose assessment 
deserves attention to ensure accuracy for estimates of clearance and 
distribution volume in the scientific literature and for registration 
purposes, especially for bioequivalence studies.
Disclosure of Interest: N. Perrottet Ries: None declared. F. Brunner-
Ferber: Consultant for BioPartners. E. Grouzmann: None declared. 
F. Spertini: None declared. J. Biollaz: Grant/research support from 
BioPartners. T. Buclin: None declared. N. Widmer: None declared.
OC006—CritiCal review Of the validatiOn 
PrOCess Of six PrediCtive BiOmarkers: hOw 
GOOd is the Quality and Quantity Of the 
evidenCe?
J.S. Peñataro1*; N. Riba1; V. Domínguez1; J. Camarero2;  
X. Carné1,3; and G. Calvo1,3
1Clinical Pharmacology Department, Hospital Clinic, Barcelona, 
Spain; 2Spanish Agency of Medicines and Medical Devices, 
Madrid, Spain; and 3University of Barcelona, Barcelona, Spain
Introduction: Increasing efforts have been made on the research 
of new predictive biomarkers in drug development, particularly in 
oncology. In this context, the validation process represents a difficult 
task with some potential methodologic limitations. In the present 
study, we will perform a critical review of the validation process of 
6 key biomarkers in oncology.
Patients (or Materials) and Methods: Six biomarkers were selected 
considering their relevance in drug development over the last dec-
ade in oncology: HER-2, EGFR, KRAS, C-KIT ALK, and C-Met. 
A review of literature was performed in PubMed, Cochrane, and 
EMBASE, and in regulatory agencies public websites. A critical 
review of available data in relation to regulatory requirements (EMA 
and FDA) has been conducted considering the following elements: 
at which stage of drug development the biomarker was considered 
in defining the target population; type of clinical data used for the 
biomarker validation process; impact of the biomarker in the final 
labeling; and availability of a standardized test applicable in clinical 
practice.
Results: Results are displayed according to recommendations of 
regulatory agencies on the necessary procedural steps for the valida-
tion process preapproval.
Conclusion: Data analyzed allow to distinguish 2 different scenarios. 
Those situations in which the biomarker development was the con-
sequence of a primarily failing drug development strategy (EGFR 
and KRAS) and those in which the biomarker was a key element 
prospectively considered in drug development (ALK, HER2, C-KIT 
and C-met). Regulatory decisions were adopted sometimes based on 
purely retrospective strategies. The authors will critically describe 
such circumstances and the potential clinical implications of such 
decisions.
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Introduction: An integrated final exam for medical students was 
introduced at Karolinska Institutet, Stockholm, Sweden, in 2012. 
The exam is scenario based and consists of six 20-minute stations, 
1 of which has been designed to assess clinical pharmacology (CP) 
skills. The overall aim of the exam is to assess the knowledge (both 
triggering  
facts
labeling  
implications
standarized  
test
HER-2 Biomarker-based 
drug development
Restricted labeling to 
HER2 overexpression or 
HER2 gene amplification
+
EGFR Failed studies in 
NSCLC
Unrestricted labeling 
in US
−
Negative opinion in EU −
EGFR+ patients 
at a later stage 
once prospectively 
validated
KRAS Failed studies in 
mCRC
KRASwt in EU
Negative opinion in US
KRASwt at a later stage 
in US and EU once 
prospectively confirmed
+
C-KIT Exploratory 
analyses through 
the different 
indications
Not reflected in labeling −
ALK Biomarker-based 
drug development
Restricted labeling to 
anaplastic lymphoma 
kinase (ALK)-positive in 
NSCLC
+
C-Met Biomarker-based 
drug development
Not reflected yet −
